Table 5 Hematology analyses from male BALB/c mice injected with IRDye800CW-nimotuzumab
From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Parameter | baseline | day 2 | day 14 | (male) | ||
|---|---|---|---|---|---|---|
vehicle | Nz-800CW | vehicle | Nz-800CW | |||
mean ± sd | mean ± sd | mean ± sd | unit | |||
GR | 5.5 ± 0.9 | 2.7 ± 1.0 | 4.3 ± 1.4 | 2.7 ± 0.7 | 5.4 ± 1.6 | % |
Hct | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.5 ± 0.0 | 0.5 ± 0.0 | L/L |
Hgb | 156 ± 19 | 146 ± 20 | 159 ± 23 | 166 ± 4 | 169 ± 3 | g/L |
LY | 80.3 ± 2.8 | 85.2 ± 4.5 | 81.5 ± 3.2 | 87.5 ± 1.6 | 80.6 ± 3.6 | % |
MCH | 18.7 ± 0.2 | 19.1 ± 0.3 | 19.0 ± 0.2 | 18.9 ± 0.1 | 18.6 ± 0.2 | gp |
MCHC | 321 ± 1 | 321 ± 1 | 322 ± 1 | 322 ± 0.1 | 322 ± 0.1 | g/L |
MCV | 58.2 ± 0.6 | 59.4 ± 0.8 | 59.0 ± 0.7 | 58.8 ± 0.2 | 57.6 ± 0.6 | fL |
MO | 14.2 ± 3 .0 | 12.1 ± 3.8 | 14.1 ± 2.0 | 9.8 ± 1.7 | 13.9 ± 2.6 | % |
Plt | 860 ± 228 | 900 ± 164 | 809 ± 219 | 923 ± 90 | 1001 ± 78 | × 109/L |
RBC | 8.8 ± 0.2 | 8.9 ± 0.4 | 8.7 ± 0.3 | 8.7 ± 0.1 | 9.1 ± 0.2 | × 1012/L |
RDW | 15.6 ± 0.3 | 15.9 ± 0.8 | 15.9 ± 0.6 | 16.9 ± 1.9 | 19.6 ± 5.6 | % |
WBC | 1.4 ± 0.3 | 2.1 ± 0.7 | 1.5 ± 0.8 | 1.6 ± 1.0 | 2.5 ± 1.1 | ×109/L |